.Nennstiel et al. Journal of Health-related Case Reports 2014, eight:34 http://jmedicalcasereports/content/8/1/Page four ofTable 3 Final results of multichannel impedance-pH monitoring in the course of pucalopride-treatment [7]Patient 1 MII and/or pH Medication during monitoring during monitoring: therapy with – Pantoprazole 40mg prucalopride per day + Prucalopride 2mg each day Acid reflux time: Patient two Medication through monitoring: – Pantoprazole 40mg per day + Prucalopride 2mg each day 0.1 Acid reflux time: Patient 3 Medication through monitoring: – Omeprazole 20mg per day + Prucalopride 2mg every day 0.9 Acid reflux time: 1.2 Acid reflux time: General reflux episodes: Mixed or liquid reflux episodes: Gaseous reflux episodes: 1.9 59 40 19 39 Acid reflux episodes: Non- and/ or weakly acid reflux episodes: 20 Patient four Medication during monitoring: – Prucalopride 2mg per dayOverall reflux episodes: 46 Mixed or liquid reflux five episodes: Gaseous reflux episodes: Acid reflux episodes: Non- and/or weakly acid reflux episodes: *Scale 0 to10: 0 = none; ten = unbearable 41 17Overall reflux episodes: 108 Mixed or liquid reflux 100 episodes: Gaseous reflux episodes: Acid reflux episodes: Non- and/or weakly acid reflux episodes: 8 32Overall reflux episodes: 83 Mixed or liquid reflux 74 episodes: Gaseous reflux episodes: Acid reflux episodes: Non- and/or weakly acid reflux episodes: 9 26Subjective symptom scores* Subjective symptom scores* Subjective symptom scores* Subjective symptom scores* – Heartburn + Regurgitation: three – Heartburn + Regurgitation: five – Regurgitation: three Limitation of every day life: three SI: optimistic for heartburn and regurgitation Limitation of every day life: five SI: good for heartburn, negative for regurgitation Limitation of every day life: 3 SI: damaging for regurgitation – Heartburn, Globus, Bloating: 4 Limitation of daily life: 9 SI: unfavorable for heartburn, globus and bloatingMII ?multichannel impedance monitoring, SI ?symptom index.3-Chloro-1H-indazole-5-carboxaldehyde custom synthesis Subjective symptom scores are according to the questionnaire previously described by Becker V et al.1233717-68-4 custom synthesis [7].PMID:23381601 SAP, Symptom association probability; SI, Symptom index.PatientThis 40-year-old Caucasian lady with chronic constipation reported obtaining heartburn, globus and bloating for three months. First gastroscopy showed no axial herniation or erosive reflux lesions; nonetheless, a Helicobacter pylori-induced gastritis was detected. Nonetheless, soon after effective eradication of H. pylori (confirmed by a C-13 breath test) and continued regular PPI therapy, symptoms persisted. As a result, she quit PPI therapy and also the initial combined pH and MII monitoring was conducted with no any medication. In pH monitoring we found nonpathologic values. MII monitoring revealed elevated general reflux episodes (n = 108) and, in particular, elevated acid reflux episodes (n = 71). Her SI was constructive for heartburn, globus and bloating. Her subjective assessment for these symptoms was “9” along with the influence of these symptoms on her daily life was also stated as “9” by our patient. The second MII monitoring, following initiation of prucalopride therapy, showed a decrease of symptoms overall (n = 59), acid (from 71 to 39) and non- and/or weakly acid (from 37 to 20) reflux episodes. Her SI was damaging for heartburn, globus and bloating. The subjective score for these symptoms decreased to a “5”; nonetheless, subjective assessment with the influence of these symptoms on her every day life remained at “9”.Discussion This case series indicates for the initial time that prucalopride, singl.